FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Nobuaki Fujise

Research Profile

Living Beings

Chemicals & Drugs

Anatomy

Livers

Disorders

Co-author Network

Publications

TOP 3
Shizuko Abe; Yoshiaki Tanaka; Nobuaki Fujise; Tsuyoshi Nakamura; Hiroaki Masunaga; Takashi Nagasawa; Minoru Yagi
An antioxidative nutrient-rich enteral diet attenuates lethal activity and oxidative stress induced by lipopolysaccharide in mice.
Yasushi Yamashita; Nobuaki Fujise; Eiichi Imai; Hiroaki Masunaga
Reduction of monocrotaline-induced hepatic injury by deleted variant of hepatocyte growth factor (dHGF) in rats.
Atsuko Mizuno; Takeshi Kanno; Masaki Hoshi; Osamu Shibata; Kazuki Yano; Nobuaki Fujise; Masahiko Kinosaki; Kyoji Yamaguchi; Eisuke Tsuda; Akihiko Murakami; Hisataka Yasuda; Kanji Higashio
Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Nobuaki Fujise (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Shizuko Abe; Yoshiaki Tanaka; Nobuaki Fujise; Tsuyoshi Nakamura; Hiroaki Masunaga; Takashi Nagasawa; Minoru Yagi
An antioxidative nutrient-rich enteral diet attenuates lethal activity and oxidative stress induced by lipopolysaccharide in mice.
JPEN. Journal of parenteral and enteral nutrition 2007;31(3):181-7.
2002: Yasushi Yamashita; Nobuaki Fujise; Eiichi Imai; Hiroaki Masunaga
Reduction of monocrotaline-induced hepatic injury by deleted variant of hepatocyte growth factor (dHGF) in rats.
Liver 2002;22(4):302-7.
2002: Atsuko Mizuno; Takeshi Kanno; Masaki Hoshi; Osamu Shibata; Kazuki Yano; Nobuaki Fujise; Masahiko Kinosaki; Kyoji Yamaguchi; Eisuke Tsuda; Akihiko Murakami; Hisataka Yasuda; Kanji Higashio
Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis.
Journal of bone and mineral metabolism 2002;20(6):337-44.
2002: Hirohiko Arisawa; Kenji Fukui; Eiichi Imai; Nobuaki Fujise; Hiroaki Masunaga
General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 4th communication: Effects on gastrointestinal, urinary and reproductive systems and other effects.
Arzneimittel-Forschung 2002;52(4):225-32.
2002: Kazuhiko Kurosawa; Kosaku Takahashi; Nobuaki Fujise; Yasushi Yamashita; Naohiro Washida; Eisuke Tsuda
SNF4435C and D, novel immunosuppressants produced by a strain of Streptomyces spectabilis. III. Immunosuppressive efficacy.
The Journal of antibiotics 2002;55(1):71-7.
2002: Hirohiko Arisawa; Kenji Fukui; Nobuaki Fujise; Hiroaki Masunaga
General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 2nd communication: effects on somatic nervous system and on autonomic nervous system and smooth muscle.
Arzneimittel-Forschung 2002;52(2):81-8.
2002: Hirohiko Arisawa; Eiichi Imai; Nobuaki Fujise; Kenji Fukui; Hiroaki Masunaga
General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 1st communication: effects on general behavior and central nervous system.
Arzneimittel-Forschung 2002;52(1):14-20.
2002: Shin-ichi Mochizuki; Nobuaki Fujise; Kanji Higashio; Eisuke Tsuda
Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats.
Journal of bone and mineral metabolism 2002;20(1):14-20.
2000: A Shiota; Yasushi Yamashita; Nobuaki Fujise; Hiroaki Masunaga; H Yasuda; Kanji Higashio
A deleted form of human hepatocyte growth factor stimulates hepatic lipogenesis and lipoprotein synthesis in rats.
Pharmacological research : the official journal of the Italian Pharmacological Society 2000;42(5):443-52.
1999: Y Uematsu; Nobuaki Fujise; Kazuhiro Kohsaka; Hiroaki Masunaga; Kanji Higashio
Effective administration route for the deleted form of hepatocyte growth factor To exert its pharmacological effects.
Journal of pharmaceutical sciences 1999;88(1):131-5.
1998: Takuhiko Akatsu; Takehiko Murakami; Katsuhiro Ono; M Nishikawa; Eisuke Tsuda; S i Mochizuki; Nobuaki Fujise; Kanji Higashio; Kazuo Motoyoshi; Michiko Yamamoto; Naokazu Nagata
Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy.
Bone 1998;23(6):495-8.
1998: Atsuko Mizuno; N Amizuka; K Irie; Akihiko Murakami; Nobuaki Fujise; T Kanno; Y Sato; N Nakagawa; Hisataka Yasuda; S i Mochizuki; T Gomibuchi; Kazuki Yano; Nobuyuki Shima; Naohiro Washida; Eisuke Tsuda; T Morinaga; Kanji Higashio; H Ozawa
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.
Biochemical and biophysical research communications 1998;247(3):610-5.
1998: Akihiro Tomoyasu; Masaaki Goto; Nobuaki Fujise; S i Mochizuki; Hisataka Yasuda; T Morinaga; Eisuke Tsuda; Kanji Higashio
Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor.
Biochemical and biophysical research communications 1998;245(2):382-7.
1998: Yasushi Yamashita; A Shiota; Nobuaki Fujise; H Ogawa; Hiroaki Masunaga; H Yasuda; Kanji Higashio
Effects of the deleted form of hepatocyte growth factor on serum hyaluronate levels in rats with liver cirrhosis.
The Journal of veterinary medical science / the Japanese Society of Veterinary Science 1998;60(3):359-60.
1998: Hisataka Yasuda; Nobuyuki Shima; N Nakagawa; S i Mochizuki; Kazuki Yano; Nobuaki Fujise; Y Sato; Masaaki Goto; Kyoji Yamaguchi; M Kuriyama; T Kanno; Akihiko Murakami; Eisuke Tsuda; T Morinaga; Kanji Higashio
Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.
Endocrinology 1998;139(3):1329-37.
1998: Hiroaki Masunaga; Nobuaki Fujise; A Shiota; H Ogawa; Y Sato; Eiichi Imai; H Yasuda; Kanji Higashio
Preventive effects of the deleted form of hepatocyte growth factor against various liver injuries.
European journal of pharmacology 1998;342(2-3):267-79.
1997: Hiroaki Masunaga; Nobuaki Fujise; Yasushi Yamashita; A Shiota; H Yasuda; Kanji Higashio
Deleted form of hepatocyte growth factor (dHGF) increases the number of platelets in rats with liver cirrhosis.
Liver 1997;17(4):192-7.
1996: H Yasuda; E Imai; A Shiota; Nobuaki Fujise; T Morinaga; Kanji Higashio
Antifibrogenic effect of a deletion variant of hepatocyte growth factor on liver fibrosis in rats.
Hepatology (Baltimore, Md.) 1996;24(3):636-42.
1996: Hiroaki Masunaga; Nobuaki Fujise; A Shiota; Yasushi Yamashita; H Yasuda; Kanji Higashio
Amelioration of disordered hepatic protein synthesis by the deleted form of hepatocyte growth factor in models of liver failure in rats.
The Journal of pharmacy and pharmacology 1996;48(8):876-9.
1990: Makoto Yoshihama; K Tamura; M Nakakoshi; J Nakamura; Nobuaki Fujise; G Kawanishi
14 alpha-hydroxyandrost-4-ene-3,6,17-trione as a mechanical-based irreversible inhibitor of estrogen biosynthesis.
Chemical & pharmaceutical bulletin 1990;38(10):2834-7.
1990: N Nakahara; Nobuaki Fujise; G Kawanishi; F Mizobe
Central muscarinic activities of an M1-selective agonist: preferential effect on reversal of amnesia.
Brain research 1990;507(1):172-5.